Effects of progesterone treatment in polycystic ovary syndrome on pulmonary functions
[ X ]
Tarih
2019
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Refik Saydam National Public Health Agency (RSNPHA)
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Objective: We aimed to evaluate patients with polycystic ovary syndrome in terms of respiratory function tests and to investigate the relationship between progesterone therapy and pulmonary functions. Methods: Fifty patients, who were diagnosed polycystic ovary syndrome (PCOS) according to Rotterdam criteria, at gynecology and obstetrics clinic of a research and training hospital included in the study group. Fifty healthy person were included in the control group. Both groups were evaluated with pulmonary function tests (PFT) at pulmonary medicine clinic of a university hospital. Independent from PFT survey, the patient group was treated with two cycles of medroxyprogesterone acetate between 16 and 25 days of the cycle as the standart follow up and treatment at gynecology and obstetrics clinic. Afterwards they were evaluated with PFT again. Statistical analysis of independent measurements were analyzed by Student's t-test. Mann-Whitney U, Wilcoxon test was used to analyze the data without normal distribution. P value < 0.05 was considered as significant. Results: Post-treatment pulmonary function test values were compared with pre-treatment values. Posttreatment forced expiratory volume during the first second (FEV1) and forced vital capacity (FVC) values were found increased after the treatment. Conclusion: Although the pulmonary function of PCOS patients were not different from that of the healthy female population, progesterone treatment has been shown to increase FEV1 and FVC parameters. © 2019, Refik Saydam National Public Health Agency (RSNPHA).
Açıklama
Anahtar Kelimeler
Medroxyprogesterone acetate, Polycystic ovary syndrome, Pulmonary function test
Kaynak
Turk Hijyen ve Deneysel Biyoloji Dergisi
WoS Q Değeri
Scopus Q Değeri
Q4
Cilt
76
Sayı
2
